Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|May 14, 2026

The BioPharm Brief: Immunotherapy Wins, Next-Gen CAR-T, and Hope for Duchenne Patients

Today’s BioPharm Brief covers Phase III clinical trial advances in bladder cancer from AstraZeneca , new in vivo CAR-T financing from Create Medicines, and positive Duchenne muscular dystrophy gene therapy results from REGENXBIO.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today, we’re looking at positive late-stage oncology data from AstraZeneca, fresh investment in in vivo CAR-T technology, and encouraging pivotal Duchenne muscular dystrophy gene therapy results from REGENXBIO.

First, AstraZeneca reported positive interim results from its Phase III VOLGA trial evaluating an investigational perioperative immunotherapy combination in patients with muscle-invasive bladder cancer who are ineligible for or declined cisplatin chemotherapy. According to the company, the regimen demonstrated statistically significant improvements in both event-free survival and overall survival compared with surgery alone. AstraZeneca also said the safety profile was consistent with previously known data for the therapies involved. The findings add to growing industry interest in perioperative immunotherapy approaches for earlier-stage cancer treatment.

Meanwhile, Create Medicines announced it secured 122 million dollars in financing to support development of its in vivo CAR-T pipeline. The company is developing technologies designed to engineer CAR-T cells directly inside the body, rather than relying on traditional ex vivo manufacturing processes. Interest in in vivo approaches continues growing as developers look for ways to simplify production, reduce manufacturing complexity, and potentially expand patient access to cell therapies.

And finally, REGENXBIO announced positive topline Phase III results from its AFFINITY DUCHENNE study evaluating investigational gene therapy RGX-202 for Duchenne muscular dystrophy. The company reported that the trial met its primary endpoint, with 93 percent of participants achieving targeted microdystrophin expression levels at Week 12. Interim findings also showed a statistically significant correlation between microdystrophin expression and functional improvement in evaluated patients. REGENXBIO said the therapy was generally well tolerated and plans to pursue a potential accelerated approval pathway beginning in 2027.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of key developments

  • AstraZeneca reported positive Phase 3 VOLGA trial results in muscle-invasive bladder cancer using perioperative Imfinzi plus enfortumab vedotin.
  • Create Medicines raised $122 million to advance in vivo CAR-T therapy development and platform technologies.
  • Both developments highlight continued momentum in oncology innovation and next-generation therapeutic platforms.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more